Last week at the Consumer Electronics Show (CES) in Las Vegas, “Longevity” effectively replaced “Wellness” as the dominant health theme. The shift was distinct: products moved away from simple fitness tracking (steps and calories) toward clinical-grade biomarkers and biological age. The biggest buzz wasn’t about tracking health KPIs, but measuring how fast you are aging (e.g., Withings’ Body Scan 2 and NuraLogix’s Longevity Mirror).
This narrative was reinforced this week at the J.P. Morgan Healthcare Conference in San Francisco, where Longevity has graduated from a niche side topic to a central pillar of the agenda. The conversation is now framed as “Healthspan” (extending the healthy years of life) and “Metabolic Health.”
For many institutional investors, the narrative has flipped from “Aging Risk” (fewer workers, higher inflation) to the “Longevity Economy” (monetizing the demand for healthspan innovation, senior housing, and retirement income solutions).
The demographic data is staggering: The oldest Baby Boomers (born in 1946) turn 80 years old this year. This is a critical threshold – 80 is the demographic tipping point where healthcare costs triple and the need for assisted living surges. For the first time in history, there are now more people on the planet aged 65 years and older compared with children younger than 5 years.
The result is a “Silver Economy” valued at over $17 trillion. In the current economic environment, a demographic cohort that holds ~70% of disposable wealth and requires specific products – from healthcare to specialized housing – is one of the few guaranteed growth sectors.
In this week’s note, we focus on three promising sub-sectors of the longevity economy. Note that we have previously explored the fourth pillar – Senior Living – in our April 24, 2025 publication The Age of Opportunity: Investments in Eldercare.
1. Lifestyle, Prevention & Nutrition
For decades, the global healthcare model has operated essentially as “sick care,” intervening only when biological systems fail. The goal is no longer just lifespan, but healthspan, so that vitality lasts as long as the heartbeat.
This shift is creating a massive, recession-resistant market for active prevention. The one billion people over 60 are not looking to spend their accumulated wealth on hospital stays; they are deploying capital into nutrition, functional mobility, and metabolic management to preserve their independence.
Importantly for investors, the winners in this sub-sector are not necessarily the high-risk biotech moonshots, but the established players who already have brand loyalty and can industrialize prevention. These companies are poised to benefit from sticky, recurring revenue streams – once a consumer integrates a metabolic or nutritional protocol, churn is incredibly low because the product transitions from a discretionary choice to a biological necessity.
Companies that have successfully developed a direct-to-consumer relationship are identified below:
- Jamieson Wellness (JWEL-CA): As the “grey wave” creates a structural tailwind for supplements, Jamieson’s 100-year heritage offers a moat of trust in an unregulated industry. Their aggressive expansion into China – where the aging demographic is exploding – provides a significant growth lever beyond mature North American markets.
- Abbott Laboratories (ABT-US): While often cited for medical devices, Abbott’s nutrition division is the unsung hero of longevity. Nutritional drinks like Ensure and Glucerna effectively monetize the need for muscle mass preservation and metabolic control, addressing the two biggest enemies of aging: sarcopenia (muscle loss) and diabetes.
- Haleon (HLN-GB): The world’s largest pure-play consumer health company (spun out of GSK/Pfizer) is a prime example of “brand power as pricing power.” With a portfolio spanning oral health to vitamins (Centrum), they are positioned as the default choice for the daily maintenance routine of the global middle class.
2. Biopharma, Devices & Medical Innovation
This sector acts as the high-beta growth engine of the longevity theme. We are entering a “Golden Age” of biology where AI is accelerating drug discovery and the narrative has shifted from “curing cancer” to targeting the upstream drivers of aging: metabolic dysfunction, inflammation, and cellular decay.
The investment thesis here is about solving the “hardware” and “software” problems of the human body simultaneously. As the population crosses the 80-year demographic tipping point, demand is pivoting from acute crisis management to systemic maintenance.
We favor companies that provide the essential infrastructure for this shift – whether it’s chemically reprogramming metabolism (such as GLP-1 medication) or physically upgrading the chassis (i.e. surgical interventions) to help keep an aging population both mobile and independent:
- Stryker Corp (SYK-US): The “Gold Standard” for medical equipment and implants. As people live longer and stay active, they inevitably wear out their joints. Stryker is the dominant player in the replacement cycle (knees and hips) and surgical robotics (Mako), effectively selling the spare parts required to maintain mobility in the final decades of life.
- Intuitive Surgical (ISRG-US): The enabler of geriatric surgery; older patients often cannot withstand the trauma of open surgery. Intuitive’s da Vinci robotic ecosystem allows for complex, minimally invasive procedures with significantly faster recovery times. They are the infrastructure that makes necessary interventions survivable for the frailest demographic.
- Alcon (ALC-US): The “Optical Upgrade” play. Cataracts are a guaranteed biological eventuality – virtually 100% of the population will develop them if they live long enough. Alcon dominates the surgical ecosystem to fix this, holding global leadership in intraocular lenses (IOLs). Their premium PanOptix and Vivity lenses allow seniors to not just restore vision but upgrade it, eliminating the need for glasses entirely.
- Novo Nordisk (NOVO.B-DK): The leader in the “Metabolic Era.” Beyond the immediate success of GLP-1s for weight loss, Novo is rewriting the code for aging. By addressing metabolic instability – a core driver of cardiovascular disease and inflammation – they are transitioning from a diabetes specialist to a generalist provider of systemic biological resilience.
3. Diagnostics, Monitoring & Digital Health
If biopharma provides the upgrades, the diagnostics sector provides the essential health dashboard. For the vast majority of medical history, healthcare has been flown “blind” – relying on lagging indicators like annual blood draws or the sudden appearance of symptoms. In an aging society, this latency is fatal: treating Stage 4 cancer is exponentially more expensive and less successful than treating Stage 1. Therefore, the economic logic of the longevity economy rests entirely on early detection.
The investment opportunity lies in the technologies that act as the body’s early warning system – detecting metabolic drift, neurodegeneration, and structural decay before they become disasters:
- DexCom (DXCM-US): The undisputed standard for Continuous Glucose Monitoring (CGM). DexCom is successfully bridging the gap between “sick care” and “healthspan,” expanding from a diabetic user base to a growing market of “health seekers.” By giving users real-time visibility into their metabolic response to food and sleep, they are effectively gamifying the prevention of metabolic aging.
- GE HealthCare (GEHC-US): Spun off as a pure-play, GE dominates the high-barrier imaging market (MRI/CT) required to diagnose neurodegenerative diseases like Alzheimer’s in their nascent stages. As new Alzheimer’s drugs come to market, the demand for GE’s high-resolution imaging infrastructure will serve as the mandatory “gatekeeper” for treatment eligibility.
- Hologic (HOLX-US): The global leader in women’s health diagnostics. Since women statistically outlive men, Hologic acts as a demographic pure-play on the “Silver Economy.” Crucially, their dominance extends beyond mammography to bone densitometry – the critical diagnostic tool for fighting osteoporosis and preventing the falls and fractures that often signal the end of independent living.
Beyond their alignment with the structural “Silver Economy” megatrend, our selected names demonstrate robust financial health. Unlike speculative biotech plays, these are cash-generative incumbents with defensible moats. This quality is visible in the performance divergence: while the broader S&P Health Care Equipment ETF (XHE) has returned -4.7% over the last three years, the medical equipment and infrastructure leaders in our selection—such as Stryker and Abbott—have delivered strong positive alpha. This reinforces our thesis that in the longevity economy, owning the dominant “maintenance capex” providers offers a superior risk-adjusted return compared to broad index exposure.
If 2025 taught us anything, it is that the impact of Trump’s political orientations on equity prices is often far from what conventional wisdom would predict. In our final note of last year, we highlighted a plethora of sustainability themes that performed far differently than consensus expectations predicted under a Trump government.
Indeed, last year showed investors, including your SMS editors, the need for critical ignoring in order to truly parse the signal from the noise. Though we doubt that Trump will take less space in the news cycle, our 2026 investment outlook is a return to two fundamental questions of investing:
- Will monetary and fiscal policy settings offer a tailwind or headwind to equity prices?
- Which economic sectors offer the most attractive risk/reward backdrop to investors?
Our relatively sanguine view on equity markets stems from a cool-headed analysis of policy settings. In the U.S., fiscal policy is projected to be modestly positive in 2026 whereas it was restrictive in 2025. There is likely to be Q1 pop in fiscal thrust – thanks to a resumption in federal spending after the shutdown, as well as OBBBA tax cuts that will boost spending (see chart below).
Meanwhile, as the chart below highlights, overall financial conditions have been favourable for some time, and it is hard to see that changing for the foreseeable future; politics at the Fed suggest a dovish configuration for 2026 and beyond.
To be sure, an economic recession in the U.S., occurring in parallel with major weakness in China would put a damper on our moderately bullish thesis. The American labor market is a sore spot – the majority of jobs created over the past year have been in the hospitality and health care sectors, both of which offer under-average wage compensation. But hiring managers still report unfilled positions and continue to be optimistic about hiring; we are resolved to wait until there are definitive signs of a labor market breakdown or unmistakable evidence of a recession before becoming more bearish on risk assets.
Given the above-described policy settings: which sectors offer an attractive risk/reward backdrop to investors in 2026? Below we highlight six sustainable equity investment ideas that can benefit from mildly favorable policy settings that we believe are primed to outperform.
Idea #1: The Grid Super-Cycle: Expansion vs. Integration
Investing in the grid is hardly a contrarian take in 2026. In fact, it is arguably the most crowded trade on the street – but the “why” matters more than the “what.” Most analysis treats the grid as a monolith, indiscriminately buying utilities and equipment makers. We see it differently. The global grid trade has bifurcated into two distinct markets with opposing drivers: the U.S. is in a frantic race for expansion (more capacity for AI), while Europe is fighting for integration (more stability for renewables).
The U.S. “Expansion” Trade: As we discussed in our October 16, 2025, note “The Energy Transition Just Switched Time Zones”, the U.S, power grid is in aggressive growth mode for the first time in two decades. The driver is no longer just replacing aging poles; it is raw load growth from data centers requiring massive amounts of firm power.
- The Signal: The clearest sign of scarcity came in July 2025, when PJM (the largest U.S. grid operator) saw its 2026/2027 capacity auction clear at a record $329.17 per MW-day – a near 10x spike from previous lows. This proves that demand has critically outpaced supply, confirming that the market is now forced to pay unprecedented premiums to secure the limited “connected capacity” required for growth.
- The Play: Buy the “Connectors.”
- Eaton (ETN-US): The hardware monopoly. Data centers cannot function without their specific switchgear and transformers, and order books are full well into 2027. Critically, the stock has not followed the hype yet (-4% in 2025), making it a prime candidate for a catch-up trade as earnings finally reflect the backlog.
- Quanta Services (PWR-US): As the dominant “boots on the ground” builder, Quanta’s record backlog is proof that while AI moves at the speed of light, power still moves at the speed of construction.
The Rest of World “Integration” Trade: Outside of the U.S., the narrative flips. Europe isn’t just fighting for more power; it is fighting to stabilize it. As renewable penetration crosses 50%, national grids are breaking under the volatility.
- The Signal: As discussed in our May 22, 2025, note “From Solar Panels to Control Panels: Why It’s Time to Focus on the Grid”, the April 2025 Iberian Blackout was a wake-up call as it proved that without massive interconnection upgrades, renewable surges can crash the system. Thus, the priority has shifted from building solar farms to building the “interconnectors” that move power across borders.
- The Play: Buy the “Integrators.”
- Nexans (NEX-PA): While Prysmian (PRY-MIL) is the safe beta, Nexans is the alpha “catch-up” trade. Prysmian trades at a premium (~20x P/E) due to its scale. Nexans, however, has transformed into a pure-play electrification proxy but still trades at a discount (~13-15x P/E). As the market digests their divestment of non-core assets and refocus on high-margin subsea cables, we expect this valuation gap to close, offering significant upside in 2026.
- Schneider Electric (Paris: SU): While Nexans and Prysmian provide the cables, Schneider provides the digital “brain.” Their software and automated switchgear manage the complex flows of renewable energy. They are essential for preventing the kind of “voltage instability” that triggered the Spanish blackout.
Idea #: 2 Dreading Natural Disasters? Add Long Positions in Dredgers
Despite the political rhetoric, the cost of natural disasters and the need for climate resilience are not going away. Finding climate adaptation plays that go beyond insurance and engineering services companies is sometimes challenging, but one niche segment that deserves more attention from investors is dredging.
Dredging companies are on the front line of combatting rising sea levels and stronger storms that threaten the reliability of ports, flood control channels, and coastal waterways. And beyond climate considerations, dredging is a necessary economic investment. Ports and inland waterways are the backbone of domestic commerce in many countries and in international trade, yet many are not maintained to their necessary depths. Inadequate dredging leads to shipping delays and higher transportation costs. Strengthening supply chains and supporting domestic manufacturing requires well functioning ports and dredging companies are critical.
Two public dredging companies of interest are Great Lakes Dredge & Dock (GLDD), which operates mostly in the U.S., and DEME Group (DEME) that derives most of its revenues in Europe.
GLDD: A large share of U.S. dredging revenue is tied to government contracts, which are influenced by appropriations cycles, regulatory approvals, and political priorities. Fortunately for GLDD, despite Trump having gutted disaster relief agencies like FEMA, funding tailwinds for coastal resiliency and port deepening remain intact -the company has strong backlog visibility (total backlog is over 1.3 times total 2024 annual revenue). Indeed, the company’s value proposition hinges on pairing the industry’s youngest and largest dredging fleet with complex project execution expertise, allowing it to capture market share and higher margins in capital deepening and coastal resiliency work. Importantly, in the U.S., dredging projects are protected from international competition: the Jones Act requires U.S.-built, U.S.-crewed vessels for domestic dredging, which provides an important moat around the company’s core revenue base: there are no real U.S. dredging companies that can compete with GLDD.
DEME: Similar to GLDD, DEME operates in both port and coastal infrastructure dredging, as well as soil and sediment remediation and the company also has significant revenue associated with Engineering, Procurement, Construction, and Installation of offshore wind (foundations, turbine installation, cables) plus oil & gas decommissioning). The company’s most important moat is its fleet modernization: DEME operates cutting-edge vessels that allow it to do work in deeper waters and complex installations that legacy fleets cannot match. Investors should note however that DEME is stock is less liquid, given that two major investors own over 70% of outstanding stock.
Over the past year, GLDD stock performance has kept pace with the S&P500, though DEME has lagged. What is more, while the S&P 500 is reaching ever higher valuations (P/E of 29 for the entire market and 23.7 excluding tech), dredging companies have been consistently getting cheaper over the past three years. Both companies currently trade at 12 times earnings, compared to historical valuations closer to 16 times. With structural tailwinds in place and large project backlogs, both companies offer good value in a critical climate adaptation sector.
Idea #3: Short Peabody Coal – The King of a Shrinking Castle
According to the U.S. Energy Information Administration (EIA) and market reports from late 2025, coal consumption by the electric power sector rose by approximately 9% to 11% compared to 2024 in the United States. This was the first year when usage of thermal coal for power generation purposes increased in more than two decades of decline. Stronger power demand coming from data centers and a frigid winter in North America both supported the price of coal pure plays such as Peabody Energy (BTU), which is trading at a five year high.
However, our expectation is that it will be difficult to notch out more coal demand from here. Although it may be true in theory that that the U.S.’ fleet of thermal coal plants has a massive amount of “spare capacity” (roughly half of the fleet sits idle on any given day), most of that capacity is unusable: old coal plants are hard to restart and are unreliable, and grid capacity near offline plants is insufficient. Overall, we do not expect that the 2025 increase in thermal coal usage is the start of a new trend. In this context, stock investors are currently pricing BTU as if their earnings are far more durable than they are.
Idea #4: Long GLP-1s: The Transition to Essential Medicine
The investment thesis for weight loss drugs is evolving from a consumer discretionary theme to a medical necessity. While 2024 and 2025 were defined by lifestyle adoption, 2026 will likely be driven by clinical indications. Recent data confirms GLP-1 efficacy in treating chronic kidney disease (CKD), heart failure, and addiction disorders. As these drugs secure approval for such indications, insurance reimbursement rates should improve, transitioning the Total Addressable Market (TAM) from a self-pay model to a covered, essential medicine model. Furthermore, the anticipated rollout of oral formulations, led by Novo Nordisk’s oral Wegovy, promises to democratize access by removing the barriers associated with cold-chain storage and injection administration.
A significant investment performance gap emerged in 2025, with Eli Lilly (LLY) appreciating approximately 40% while Novo Nordisk (NVO) corrected by roughly 40%. While Lilly executed well on its pipeline, we believe investors have over-penalized Novo for temporary supply chain constraints. Novo Nordisk remains the global incumbent with the deepest clinical data repository. We view the current valuation disparity as irrational and expect mean reversion in 2026 as Novo resolves supply bottlenecks. For investors seeking diversified exposure to the theme – and protection against single-stock volatility – the Roundhill GLP-1 & Weight Loss ETF (OZEM) offers a balanced basket of approximately 25 companies, capturing both the established duopoly and emerging biotech acquisition targets.
Idea #5: Buy a Korean Car – and the Stock
We have outlined in past notes the bullish case for Korea stocks (for example, please see “Seoul Mates: The Case for Korean Sustainability Plays”, May 1, 2025). We especially like Korean EV carmakers.
Korean car makers appear to be much more engaged in electrification compared to their U.S./Japanese counterparts, and the trade deal with the US takes some uncertainty away on the country’s ability to export to the U.S.
To be sure, consensus forecasts for global EV sales in 2026 are not particularly rosy. However, the Korean brands are poised to steal market share from other manufacturers. After all, their build quality is impressive especially given the price. For example, Kia is putting out its K5 EV car at the same price as its ICE sister K4 car. Meanwhile, Hyundai just unveiled it’s robotaxi –a testament to the company’s recent technological catch-up.
We especially like Kia at its current price – the stock is training at very low multiples relative to its peers.
Idea #6: A Word About Oil
Prior to events in Venezuela, short positions in U.S. oil services companies SLB and Halliburton were among our top 2026 investment ideas. The thesis is straightforward: oil services are the part of the supply chain most sensitive to oil prices. With WTI trading at cyclical lows below $60/bbl and a strong consensus for little upside in 2026, drilling activity is likely to remain weak. Historically, after a prolonged period at these prices, oil companies prepare to strand certain fossil fuel assets.
SLB and HAL stock prices traded higher in late 2025 while oil prices traded down—a rare deviation that doesn’t tend to last and often makes for an interesting entry point in short positions.
However, Trump’s intervention in Venezuela and plans for U.S. oil companies to re-enter the country drove a significant pop in U.S. oil companies over the past week. Our editorial team is divided as to whether this price action produces a better opportunity to short or whether to stand aside. Note that oil prices have not rallied since the January 2nd intervention and the world remains well-supplied with heavy crude. The price pop likely reflects optimism that drilling contracts will be awarded to U.S. companies at the expense of other suppliers like Alberta. Trump meets with U.S. oil executives next week to discuss Venezuela; we will wait for more clarity before becoming more bearish on related investments.
Over the last month, political and security turbulence has escalated on multiple fronts. The shooting of conservative commentator Charlie Kirk dominated headlines, amplifying the discourse around political violence. Donald Trump made waves by renaming the Department of Defense to the Department of War. Against this backdrop, Pete Hegseth has convened a special meeting of Department of War leaders this week. Across the Atlantic, a series of Russian drone incursions into allied airspace highlighted the fragility of European security.
In our previous note, “The European Defense Offensive: From Peace Dividend to War Premium”, March 6, 2025, we discussed how guns and drones can help to achieve security and how drones are reshaping entire civilian sectors. The central task for policymakers and investors is to channel these tools toward stability, innovation, and resilience.
Back to the Battlefield: The Resurgence of Geopolitics
Since 1980, we experienced a relative period of geopolitical calm, shaped by the end of the Cold War, expanding globalization, and the absence of direct large-scale conflict between major powers. However, this environment has been progressively shifting toward conflicts, with renewed great-power rivalries, regional wars, trade tensions, and escalating competition over resources and technology.
The table below shows the most important conflicts since the beginning of the century. The same conflicts are repeated as they generally remain unresolved as more are added to the list. The projected increases in defense spending for most countries in the world tend to confirm our assessment that tensions are accelerating globally.
The Drone Disruption: From Battlefields to Boardrooms
The Russian invasion of Ukraine has brought the extensive use of drone for reconnaissance and direct attacks into focus and shows how innovation changes the nature of wars. Twenty-five years ago, in Iraq and Afghanistan, insurgents relied on classic guerilla tactics of ambushes and mobility to counter Western military strength. In Ukraine however, drones now serve a similar role. Cheap, nimble, and precise, they harass supply lines and equipment much like guerilla fighters once did.
The chart below shows the exponential rise in demand for drones over the past five years as well as the continued exponential growth expected to occur in future years. As described above, military use is growing due to larger defense budgets and the transformation of armed forces towards more drone usage. In the civilian sector there are increasing commercial and societal uses.
From an investment perspective, the combination of military and non-military uses is appealing since it amounts to a certain diversification in demand; military spending does not tend to follow the economic cycle, whereas drone demand from non-military sources tends to more cyclical.
Indeed, for sustainable investors, drones are increasingly being deployed in ways that deliver tangible benefits for society:
- Agriculture: Drones enable precision farming by monitoring crop health, optimizing irrigation, and reducing pesticide use.
- Conservation: Drones are used in conservation to track wildlife populations, detect illegal logging, and monitor fragile ecosystems with far less disruption.
- Disaster response: Drones provide rapid aerial assessments after hurricanes, earthquakes, or floods, helping first responders save lives.
- Infrastructure & energy management: Drones can inspect solar farms, wind turbines, and power lines, reducing risks for workers.
Importantly, this civilian transformation of drone technology echoes a broader historical pattern: many advances that originated in military research such as GPS, the internet, and satellite imaging eventually delivered immense benefits for public use. In the same way, drones are now transitioning from instruments of conflict to powerful tools for society where demand is growing.
The Gun Market’s Surprising Stall
Surprisingly even with greater polarization, gun demand in the U.S. has plateaued following the post-COVID surge. Several forces explain this: many households already own multiple guns, crisis fatigue has diminished the urgency to arm, and inflation has constrained discretionary spending.
The chart below shows two indicators highlighting the COVID peak in gun demand and the recent plateauing in the United States; the largest market in the world. Background checks from the National Instant Criminal Background Check System (NCIS) are a good leading indicator of new gun demand in the United States whereas firearms manufacturing from the Annual Firearms Manufacturing and Export Report (AFMER) is a coincident to lagging indicator because manufacturers respond to current demand.
Despite persistently high homicide rates in the U.S., the political landscape leaves little room for meaningful gun legislation, and this affects the firearms market. Paradoxically, in the past, fears of tighter regulation have triggered surges in gun sales, i.e. people purchase guns in anticipation of not being able to in the future. However, with a Supreme Court broadly supportive of expansive Second Amendment rights, the likelihood of new restrictions is low, which removes the urgency to purchase additional firearms.
The map below shows that the U.S., Mexico and Brazil have among the highest firearms homicide rates and yet stronger gun control legislation is unlikely in the near future. In the United States, the current administration does not favor stricter rules. In Mexico, civilian ownership is tightly regulated but illicit firearms traficking is a powerful source of demand. In Brazil, Bolsanaro loosened gun laws when he was president while Lula has issued executive orders to tighten gun control because the Brazilian Congress is ambivalent to enact stronger regulation.
The Promise of Drones (Go Long) vs. the Limits of Guns (Be Short)
Unlike drones, which have evolved from military origins to offer wide-ranging civilian and environmental benefits, guns and munitions lack such positive spillover potential for society. Firearms are designed with a single purpose: to wound or kill, and their civilian proliferation is more often linked to rising homicide rates, accidents, and social costs rather than broad social gains.
The table below shows drone and drone-adjacent companies that offer societal benefits and positive financial attributes and gun companies to avoid from a sustainable investment standpoint.
The chart below shows market capitalization, sustainability scores, growth in sales and price to sales for companies in our targeted long and short sectors There are not yet many large companies considered to be specializing in drones; the larger companies like Nokia, Honeywell and Leonardo manufacture components used in drones as part of their much larger organization. The same can be said for gun manufacturers as they remain small capitalization. As expected from our sectoral analysis above, drone companies are experiencing strong growth: for example, Red Cat has had exceptional growth in the last five years (78% growth in sales), it is also expected to continue as its price-to-sales of 128 highlights. On the other hand, gun companies have had close to zero growth in sales and trade at depressed price-to-sales. We expect this trend to continue: high valuation in the growth segment of drones and low valuation in the stagnating gun segment.
Nine months into Trump’s presidency, its contours are taking shape. Beyond campaign promises—tax cuts, manufacturing revival, and drilling expansion – the U.S. government has taken a strong tack toward interventionism. From interference at the Fed to taking stakes in American companies, Trump’s republicanism is vastly different from preceding Presidents of the same party.
Indeed, Trump’s growing intervention, especially in corporate affairs, is fueling concerns that the U.S. is shifting away from the so-called laissez-faire economy. That said, with equity markets at new highs and both government and corporate bond yields trading in a relatively tight range, one might be hard pressed to find evidence that it matters, yet!
In 2021, we published a note ( “Macro Goes ESG” July 8, 2021) that outlined our high conviction view that fiscal and industrial policy would become dominant policy levers in the coming decade. Although we were far too optimistic that interventionist governments would address voter preferences such as climate change and socioeconomic inequalities, our forecast of government interventionist policies is proving true.
Important for investors is that unlike monetary policy which “lifts (sinks) all boats”, fiscal and industrial policy creates winners and losers. This is true for sustainability themes and financial markets at large.
In today’s Macro Meets Sustainability quarterly update, we discuss the three main U.S. government interventions that have evolved since Trump took office.
- Mar-A-Lago and USD: Beware the Kindleberger Trap
The Kindleberger Trap – named for economic historian Charles Kindleberger – posits that global stability depends on a leading power that is willing and able to supply public goods that benefit the international community. When the dominant power fails to fulfill this role, the international system becomes prone to conflict and economic crisis.
For investors, the essential public good that keeps the global economy out of the Kindleberger trap is the U.S. dollar acting as the world’s reserve currency. Reserve currencies are necessary in global trading systems to facilitate international transactions and act as a store of value, and they tend to impose two characteristics on the reserve status country:
- The reserve status country operates with a currency that is likely to be chronically expensive/overvalued because the demand for the currency is greater than without reserve status. This makes export-oriented businesses less competitive and contributes to a larger trade deficit.
- The reserve status country’s companies and financial institutions benefit from easier access to and lower cost of capital and often correspond to higher valued companies.
The so-called Mar-a-Lago Accord is an attempt in our view to have one’s cake (low interest rates, access to capital) and eat it too (revive the domestic industrial and manufacturing sector) but does not consider the consequences of falling into a “Kindleberger trap”. If the U.S. is unable or unwilling to maintain policy that ensures the greenback as the world’s reserve currency, it is unlikely that foreign nations and investors will risk asset value erosion by currency devaluation or inflation (see the section below).
To this end, there is more evidence that investors are becoming nervous about the impacts of U.S. policy on the greenback: equity investors are aggressively increasing currency hedges. According to a recent FT article and Deutsche Bank data, over 80% of the 7 billion USD that has flowed into foreign domiciled U.S. ETFs in the past three months has been on a hedged basis, compared to 20% at the beginning of the year. In other words, investors still want to own U.S. equities but are wary of the currency.
The bottom line is the current U.S. administration’s desire to decrease the trade deficit risks obliterating a key public good – a stable reserve currency – and sending the global economy into a Kindleberger trap, with the concomitant increase in volatility in financial markets. We believe that currency hedging is fully justified for non-U.S. investors exposed to U.S. markets and/or the currency risk should create a significant home bias in sustainable investments.
2. Monetary Interference: Stoking Inflation
Recent events and nominations at the Fed underscore President Trump’s intention to politicize the central bank and the outcome of last week’s FOMC meeting gave a good indication of how investors should think about policy stimulus in the current regime. Recall that last week, the FOMC voted to lower interest rates while simultaneously upgrading the economic outlook and increasing its expectation for inflation over the next year (to a level well above 2%). Thus, we believe that investors should position for both lower central bank rates and higher inflation, as it marks an important deviation from the conventional central bank’s playbook. Since 1982 (when Volcker broke the back of runaway inflation), monetary policy generally fell into four quadrants:
- Interest rates are becoming stimulative (rates are below the neutral rate and falling while the economy is weakening and lower inflation is anticipated)
- Interest rates are becoming less stimulative (rates are below the neutral rate and rising while economic growth is bottoming and higher inflation is anticipated).
- Interest rates are becoming increasingly restrictive (rates are above the neutral rate and rising because the economy is running hot and higher inflation is anticipated).
- Interest rates are becoming less restrictive (rates are above the neutral rate and falling as economic growth is peaking and lower inflation is anticipated).
By signaling that rates can go lower while economic and inflation accelerates, it is becoming more probable that the Fed will de-emphasize its objective on inflation stability and focus on maximum employment and low interest rates.
Historically, low rate and higher inflation environments have favored real estate plays and other real assets. For ideas that fit squarely within a sustainability framework, please see our recent notes on this subject: It’s About to Get Real, August 21, 2025 and The Age of Opportunity: Investments in Eldercare April 23, 2025.
- Corporate Interventionism: From Invisible Hand to Tightening Grip
In 2024, the IMF published a new data set that documents emergent patterns of policy intervention associated with the return of industrial policy. In one year, they recorded over 2,500 new industrial policies worldwide, of which 71% are considered trade distorting. This is perhaps not surprising to anyone watching the news flow. In the past quarter alone, the following U.S. developments have occurred:
- the Pentagon is the largest shareholder in the most significant U.S. rare earths business (MP Materials).
- Nippon Steel acquired U.S. Steel, but only by giving the U.S. a “golden share”, which Trump has already exercised.
- the U.S. government converted a subsidy from the Chips & Science Act into a 10% ownership stake in Intel.
- Nvidia agreed to pay the U.S. 15% of their revenue from sales of AI chips in China in exchange for a government export control license.
These are perhaps the most jaw-dropping developments, not least of all because they occurred at the firm-specific level, which represents almost half of all the interventions documented by the IMF (see table below).
The IMF’s database also categorizes policy interventions by their motivating factor. Interestingly, supply chains and climate change – considerations that both fit squarely within sustainability investing – feature prominently (see the chart below). The one caveat is that the data was collected from 2009 to 2023 and researchers noted that in the most recent year, measures focused increasingly on national security, and less on competitiveness.
The rise of industrial policy and interventionist governments is far from a uniquely U.S. phenomenon (see the table below). A case in point is this month’s announcement from Canada’s Prime Minister Mark Carney, which unveiled the first phase of the country’s “nation building” projects, all five of which could be classified by the IMF as being motivated by climate change or supply chains and include energy production (nuclear), energy transport (LNG), mineral production (copper, gold) and supply chains (port expansion).
An investment backdrop that is dominated by political catalysts implies an environment where active portfolio management is necessary because sectoral, thematic, and geographic winners and losers will be produced. Critically, this applies equally to sustainability themes. While ESG has become a touchy subject and there is no longer a wholesale buying of related equity products, companies that derive revenue from specific sustainability themes (e.g. waste management, green infrastructure, carbon) have had excellent performance so far during Trump’s reign.
Sustainability winners and losers are likely to run along thematic lines that are heavily influenced by both perceived threats and actual policy pivots; carbon is an excellent example, as discussed in last week’s note (Contrarians in the Green, September 18, 2025).
Last February, our note on the food industry argued that the likelihood of ongoing food inflation coincided with the signing of President Trump’s Executive Order (EO) “Establishing the President’s Make America Healthy Again Commission”. We made the case that RFK Jr.’s pledge to take on Big Food – along with several other factors – is a potential source of inflation since it would surely increase the cost of food production (Food Fight: Policy’s Effect on Food Producers & Inflation, February 13, 2025).
The February 13th Executive Order required the MAHA commission to submit a “Make Our Children Healthy Again” strategy but the draft that was submitted earlier this month is so vague that – for now – we are removing MAHA from our list of potential food inflation pressures. Unless there are major changes to the official version (to be released in the coming weeks), the MAHA strategy is all hat and no cattle – it lacks ambition regarding two critical sustainability topics: pesticide overuse and processed food consumption.
The Ultimate “Influencer”: Big Ag
The MAHA “hope” was that RFK would implement policy to reduce pesticide use in U.S. farming practices. After all, the U.S. is second largest consumer of pesticides and continues to increase pesticide use per unit of land at a faster pace than elsewhere (see chart below).
In addition to the volume of pesticide use, the U.S. is also an outlier in terms of the types of pesticides used. According to the most recent information collected, there are over 85 pesticides that have been banned in the European Union, China or Brazil that are still permitted in the U.S. today.
The primary MAHA attack related to pesticides is glyphosate (i.e. Roundup), originally made by Monsanto, which is now owned by Bayer, the German chemical and pharmaceutical giant. MAHA (and many others) purport that glyphosate is cancer-causing. The problem is that for each study that concludes that it is, there is another (often industry-backed) that concludes that it isn’t. This has led the EPA to say that “there are no risks of concern to human health when glyphosate is used in accordance with its current label”.
A small number of giant corporations have amassed monopoly or near-monopoly power over this and other pieces of the food and agriculture system in the (see chart below) and these companies prefer the status quo.
Indeed, it didn’t take long to round up the lobbyists to push back against MAGA when it comes to pesticides: The National Corn Growers Association, The American Soybean Association, The National Association of Wheat Growers, and the International Fresh Produce Association all implored President Trump to walk back the claims made in the February MAHA Commission report and it seems that they have been a major influence.
It’s no wonder that the industry pushed back on MAHA; pesticide manufacturers had their fair share of struggles over the past several years. The chart below shows the three-year performance of the largest pesticide companies. Only Corteva, whose sales are split between both seeds and pesticides has kept pace with the broad equity benchmark.
Even more profound than MAHA threats, oversupply and aggressive price competition from China have cut deeply into both topline growth and margins of the major producers. Note that U.S. import tariffs from China will include pesticides should the 90-day pause fail to be extended. With about half of all sales derived in the U.S., Corteva would likely continue to be the relative winner should a more protective trade backdrop develop. Note that this is not an endorsement for the company since Corteva is hardly a sustainability leader; the company ranks particularly poorly in environmental and social scores according to CSRHub and has its fair share of controversies.
Ultraprocessed Seems Ultrasafe From MAHA
The draft MAHA strategy doesn’t have much taste when it comes to Big Food either. The MAHA “hope” was that government finds ways to reduce access to unhealthy food choices. After all, on average, 55% of calories consumed by Americans come from ultra-processed foods (for youth aged 1–18 years this number is a staggering 62%!).
Last February, we explored how investors should position within the food sector should MAHA policy become a catalyst for change in the food production industry. We noted that it was a relatively straightforward exercise to find potential short candidates based on the share of sales derived from the sweets and snack foods category (Pepsi Co., Mondelez, Hershey, Nestle, Barry Callebaut and Kellanova (the latter is the snack division spun off from Kellogg’s). Half of these companies have had negative returns since the start of the year (Barry Callebaut, Kellanova, and PepsiCo) while only two have matched or exceeded the performance of the broad market (Hershey’s and Nestle).
We also noted that finding “sustainability winners” is significantly more difficult in this segment since, even once we remove the companies with the greatest revenues derived from junk food, what is left is hardly a recipe for good health. What’s more, the food majors are fraught with controversy risk; the table below shows just how rampant greenwashing is within this industry.
The MAHA draft contained little substance on how food quality could be improved or even how these companies should communicate about their products. RFK’s pet concerns (food dyes, infant formula) are addressed, but the report largely states that the major systemic problems need more “research”.
The bottom line is that we are downgrading the threat that MAHA will have much of an impact on food companies’ equity performance. Investors are most likely to turn their focus back to other drivers of returns in this sector: ingredient costs, availability of labor, and appetite suppression related to GLP-1 medication:
- Ingredient Costs: For snack food companies, the biggest concern has been the run up in cocoa prices. For example, at their February 2025 earnings call, Hershey’s predicted up to 7% of margin contraction for the year, largely due to the cost of cocoa. However, the cocoa market has since started showing signs of improvement and cocoa prices peaked in May. It is notable that confectionary companies rarely decrease their selling prices so as input costs fall, profit margins can recover and potentially even improve. Though crops like cocoa are in structural decline due to climate change, some reprieve for snack companies is likely in the near term.
- Availability of labor: fears of major labor shortages in the food sector – both at the farm and production facilities – due to Trump policy has been an important risk. There is plenty of anecdotal evidence that immigration policy is affecting the ability to source labor, but hard data is still lacking. A review of operating profit margins in the most recent quarter at some of the large food producers (e.g. Mondelez, PespsiCo, General Mills) suggest a mixed bag on whether labor and other input costs have changed significantly, with some companies reporting above-average margins and others well below.
- GLP-1 impacts: In 2023, we published a note wherein we provided calculations of the impact on food and restaurant companies due to the coming decline in calorie consumption thanks to the increasing adoption of GLP-1 weight loss medication ( “You Can Have Your Cake and Eat it Too” November 16, 2023). We forecasted that the impact on sales would be minimal. In recent earnings calls, food companies have validated our expectations. Hershey’s, General Mills, Mondelez all reported no impact on sales from GLP-1s, despite about 10% of the U.S. population now using these medications.
In sum, both the MAHA threat and other bearish factors are less acute today than six months ago. Included in our top short investment ideas of 2025 (“2025 Investment Playbook: Going Green In A Brave New World” January 9, 2025) were short positions in Mondelez (+3%), PepsiCo (-3%). While the sustainability case against these snack companies remains fervent, the catalysts for a more profound bear market have receded for now.
Real assets are uniquely positioned to thrive in a higher inflation environment because they derive revenue from long-term contracts or have built-in inflation pass-through mechanisms. Whether it’s regulated utilities with tariff escalators, toll roads indexed to inflation, or real estate entities adjusting rents upward, their cash flows tend to preserve purchasing. Moreover, these assets often own tangible, hard infrastructure that can reprice in line with rising input costs, providing both income stability and inflation protection for investors. On top, they have underperformed over the last five years.
Demand for real assets is poised to strengthen as investors seek stable, long-term cash flows with pricing power against a backdrop of chronic undersupply, following decades of underinvestment in real assets outside of China. Real assets align with sustainable investors’ goal by being involved in the energy transition, urban development and digitalization.
Moving away from 2% inflation
During the 2010s, inflation in advanced economies consistently undershot central banks’ 2% targets. Structural factors such as globalization, geopolitical stability and subdued wage growth kept price pressures muted. This led to accommodative monetary policy and historically low interest rates as policymakers were concerned about disinflation and the risk of inflation remaining too low. As the chart below shows, since 2020, the backdrop has shifted dramatically. A combination of pandemic-related supply disruptions leading to expansive fiscal stimulus and the reversal of structural factors such as demographics, de-globalization and geopolitical instability have pushed inflation well above 2%.
Moreover, the recent firing of the Bureau of Labor Statistics (BLS) commissioner following a weaker-than-expected payroll report underscores the risks of politicizing economic data and undermines the perceived neutrality of the U.S.’s economic reporting agency. Inflation is one area where the temptation to tamper with the data is greatest: social security outlays are often tied to inflation and central banks target inflation. Nudging official inflation numbers lower would reduce the cost of social security and could lower interest rates to decrease the interest cost of the debt.
Recent actions by President Trump leads us to believe that coercive actions to let the inflation target drift higher than 2% by keeping interests rate lower are likely to take place in the United States while the outlook for inflation seems tilted to the upside.
Outlook for Inflation: Upward Pressure
The table below highlights the drivers most likely to influence inflation in the future. The majority of these are likely to push inflation higher over the next five years unless artificial intelligence (AI) provides enough productivity gains to offset a shrinking labor force, re-industrialization, tariffs and growing geopolitical tensions.
Higher inflation combined with political pressure to keep interest rates low could propel a real assets recovery.
What are real assets?
At their core, real assets are tied to physical, tangible infrastructures that provide essential services. Because of their underlying economic function, they tend to offer stable and predictable cash flows, often supported by regulated pricing frameworks or long-term contracts. This income stability allows many real asset companies to maintain attractive dividend yields, making them appealing to investors seeking current income alongside potential capital appreciation. Because of the relative predictability of their cash flows, they generally carry more debt than most companies.
Another defining feature of real assets is their sensitivity to macroeconomic conditions, particularly inflation and interest rates. The long-duration nature of their cash flows means valuations can be pressured when rates rise, but the essential nature of their services often provides inflation pass-through mechanisms. This makes them valuable as a hedge against inflation, while their tangible asset base offers downside protection in periods of market stress. Furthermore, many of these assets align closely with long-term themes such as decarbonization, elder care and digitalization, often giving them defensive qualities and exposure to secular growth drivers and sustainability themes.
Sustainable Real Assets
The table below highlights how real assets are represented throughout economic sectors and how they can contribute sustainably to society.
A Sample Portfolio of the Best Aligned Companies
We single out one company in each economic segment that has the best combination of sustainability scores (using CSRHub) and alignment to sustainability according to our proprietary SMS Sustainability Alignment percentage that reflects revenue assigned to sustainability themes. As we can see from the graphic below, the companies have much better scores and alignment than the median market company.
Is the rough patch behind us?
Below are performance charts for the stock price for each real asset segment compared to a World equity Index since 2020. Very few of the companies have been able to outperform the market Index. The main reason is that interest rates were rising during the period (in response to higher inflation). Since 2023, the overall market has recovered but, for real assets, the negative effects of higher interest rates continue to be felt.
Looking specifically at each segment, starting with the sustainable environmental infrastructure companies selected, performance has been positive albeit has lagged the world index. The company Waste Management is the exception, benefitting from exceptional operational efficiency, organic growth and a good acquisition strategy.
Transportation has been having difficulties since 2022.
Social infrastructure has generally done better, especially Ensign which is providing post-acute care. It has expanded rapidly while delivering from an operational basis to a population getting older.
For natural capital and digital infrastructure, Weyerhaeuser, SBA Communications and Digital Realty have lagged the market.
Finally, to round out to 20 companies, we added a group of diversified names that operate across a few segments of real assets. Increasing interest rates have been especially difficult for them but they have been recovering lately.
Why invest now
As articulated above, the path of least resistance is higher inflation that will not be fought too hard by central banks. This should benefit companies with pricing power insulated from inflation that can tolerate a relatively high debt load.
Below is a table comparing an equal-weight portfolio of the sustainable companies we identified with a global index. The portfolio delivers greater dividends, has a lower return on equity and a higher debt load than the broad market. In other words, inflation with a weak central bank response should be a good recipe for this portfolio.
There’s a famous line in Bruce Springsteen’s Atlantic City: “Down here it’s just winners and losers, and don’t get caught on the wrong side of that line.” Today, it seems that line is drawn between those whose productivity will be augmented by AI and those who will be displaced by it.
This note examines how the AI revolution will reshape the labor market. We explore how once-enviable service-sector jobs will be affected and how Artificial General Intelligence (AGI) — if ever achieved — will likely amplify income and wealth inequalities over the coming decades. We begin with the macro view — who benefits from AI-driven productivity gains — and then drill down to industry-level effects.
Will AI Benefit Workers or Profits?
Historically, disruptive technologies have had unequal impacts depending on skill levels, income brackets, gender, and sector. Many consider AI the most significant General-Purpose Technology (GPT) since the internet in the late 1990s.
From a macro perspective, if AI can “lift all boats” by driving higher productivity, it is crucial to understand whether those gains will flow to corporate profits (and shareholders) or to workers. To answer this, we must examine how past technological breakthroughs affected worker productivity and the subsequent growth in real wages as technology integrated into daily workflows.
If productivity growth tends to translate into higher real wages over the long run, then AI’s impact on worker productivity — particularly in the services sector, which accounts for roughly 80% of GDP in many advanced economies — should, in theory, benefit those whose work is augmented by AI.
However, while labor productivity and real wage growth tracked closely until the mid-1970s, the relationship began breaking down in the 1980s as globalization expanded the labor pool and wage pressure increased. In recent decades, faster technological change — and its positive effects on productivity — has been less profitable for workers, with gains flowing largely to corporate profits.

Corporate profits as a share of national income are now at record highs, while wage share has continued to decline. Unless taxation or redistribution mechanisms change, most AI-driven gains will likely keep flowing to shareholders rather than workers.
Displaced, Augmented, or Dropped?
Every technological shift forces workers to adapt — but not all can or will. Encouragingly, a recent McKinsey & Co. survey found that many employers expect AI to create a net increase in jobs in most functions, except for service operations, supply chain management, HR, and manufacturing. While this is positive news overall, it underscores the need for workers in certain functions to adapt quickly.
Similarly, PwC’s Fearless Future: 2025 AI Jobs Barometer shows that jobs with “some exposure” to AI are still growing, but at a slower rate than jobs in occupations where AI is less relevant or not applicable.

Unlike past disruptions — such as the offshoring-driven manufacturing job losses of the early 2000s — the workers most at risk today are in coveted service-sector roles, many requiring advanced education. One striking example: the author recently saw a man in downtown Toronto wearing a sandwich board reading “Junior programmer looking for work” — a scenario almost unimaginable just two years ago. Such rapid shifts could spark political and social unrest, as displaced, highly educated workers may influence policy debates much as displaced “Rust Belt” manufacturing workers did during the 2016 U.S. election. A recent article even suggests that Silicon Valley may have mishandled the junior IT job market
A recent OECD study suggests that jobs most affected by AI are disproportionately held by highly educated white men in their prime working years — a politically influential demographic in many developed economies. Some researchers argue that this “overproduction” of educated elites could fuel additional instability.
The takeaway: not all well-educated workers will be augmented by AI to the same degree, and many will drop out of the labor market entirely, unable to integrate AI into their workflows. This is especially pronounced in services, where senior roles may benefit most from productivity gains while junior roles face displacement. As a result, workers in the top income quartiles are likely to see faster wage growth than those in lower quartiles.
Research by Apollo suggests that the two highest income quintiles — already accounting for roughly 60% of total spending — will further increase their share of consumption in the coming years.
This trend is already visible. Since 2018, earners in the top income quartiles have increased real consumption by 15%, five percentage points more than the lower quartile.

There has hardly been a week in 2025 without major developments rocking the pharmaceutical sector. The industry was spared in the first wave of U.S. tariffs but is bracing for significant disruption.
A striking signal of this is the sharp rise in U.S. pharmaceutical imports during Q1 2025, as companies rushed to stockpile drugs ahead of potential trade barriers (see chart below). In March alone, imports jumped 160% year-over-year.

This week’s note builds on our March 13 analysis (“Investing in U.S. Healthcare: The Big and Small of It”), with a focus on the pharmaceutical sector. We concentrate on three key developments:
- The potential rollout of tariffs, subject to the undergoing national-security investigation into pharmaceutical imports.
• The implementation of the May 12 executive order aimed at cutting drug prices to the lowest prices of other countries.
• The “Big Beautiful Bill” and its proposed budget cuts to federal healthcare programs, notably Medicaid.
Together, these measures reflect a strategic shift: reducing foreign reliance and curbing drug costs in the name of national security—while simultaneously delivering on tax-cut promises (which heightens pressure on federal healthcare spending). With so many moving parts—and a great deal of speculation— navigating related equity markets is increasingly complex. This note aims to identify which pharmaceutical segments and companies are most exposed to these policy pressures, and where investors may find resilience.
Why Make Health a Matter of National Security?
Healthcare spending in the U.S. is huge—reaching 16.7% of GDP in 2023, far above the 11% average among peer countries. Yet this spending hasn’t translated into better overall outcomes: Americans still face significantly higher mortality rates across major health issues, as the data below makes clear.

This disconnect becomes even more stark when considering that the U.S. makes up less than 5% of the global population but accounts for over half of total pharmaceutical sales.
Americans pay, on average, nearly three times more on prescription drugs than residents of other OECD countries, and over four times more for branded medications. This is partly due to limited price negotiation power for public insurers and longer patent protections, which delay the arrival of cheaper generics.
Framing affordability as a matter of sovereignty, the Trump administration has argued that foreign governments “extort” lower drug prices, shifting the cost burden onto Americans. Despite an executive order signed to “equalize” global drug pricing, the launch of the Section 232 national security investigation examining pharmaceutical imports could result in tariffs and ultimately push U.S. prices higher.
This higher spending is no doubt burdensome for American citizens, but it is not without benefits for the country. U.S. pharma wields immense influence: FDA approval is prioritized globally, and around 30% of drugs approved in the U.S. remain unavailable in Europe two years later.
Nonetheless, lowering drug prices has become a rare point of bipartisan agreement. Biden’s Inflation Reduction Act (IRA) initiated historic negotiations on insulin and high-cost Medicare drugs. However, Trump proposed changes that would weaken the Medicare Drug Price Negotiation Program—for instance, by delaying the inclusion of small molecule drugs by 4 additional years, which would exempt many high-cost medications from negotiation.
First, let’s turn to trade—where drug supply chains are being reframed not just as economic assets, but as strategic vulnerabilities.
Rewiring Pharma Supply Chains
The Section 232 investigation launched by the U.S. government seeks to determine whether dependence on foreign pharmaceutical imports poses a national security threat. The outcome of the investigation could be deemed a justification for tariffs, to encourage domestic production. While the formal conclusion of the investigation could take up to nine months, the imposition of tariffs may occur much sooner—potentially within weeks, according to the U.S. commerce secretary.
Trump has mentioned a 25% tariff rate on pharmaceutical imports. Countries most vulnerable to this policy shift are in Europe and Asia (particularly China and India) due to their dominant roles in the supply of active pharmaceutical ingredients to the U.S.
These regions have also developed specializations that make them essential in today’s healthcare landscape:
- India manufactures 20% of global generic drug exports and 60% of low-cost vaccine supply.
- China is a key supplier of active pharmaceutical ingredients (APIs), with 40% of global production, though most U.S. imports come from India and Europe.
- Europe is a major exporter of high-value branded drugs and biologics (medications derived from living organisms) to the U.S. Pharmaceuticals were the top EU export to the U.S. in 2024, worth nearly €80 bn. Ireland in particular hosts many manufacturing sites for U.S. pharmaceutical companies due to favorable tax structures. Ireland is the 3rd largest exporter of pharmaceuticals globally, and has around 50 US FDA approved pharma and biopharma plants. Trump is especially critical of this heavy reliance on Ireland.
Tariffs would hit generic drugs hardest—a segment that makes up 90% of U.S. prescriptions by volume. Most generics are produced abroad, especially in India. With already slim margins, a 25% duty could render some products economically unviable.
Tariffs are also particularly concerning for essential injectables like chemotherapy drugs, already prone to shortages. ING estimates a 24-week cancer drug supply could become $10,000 more expensive under proposed tariffs. The head of the Association for Accessible Medicines warns some drugs may disappear from the U.S. market entirely.
The table below highlights pharmaceutical segments and regions most exposed to tariff risk, while also identifying companies with supply chains more insulated from high-risk geographies. Our analysis focused on the 20 largest companies by market cap in each segment, along with names already included in our investment universe. Those identified under the “less vulnerable” column have been vetted for strong scores across material operational performance metrics.
The concentration of production abroad—especially for low-margin, high-need drugs—makes tariffs a blunt tool with uncertain outcomes. Critics of Trump policies argue that instead of penalizing imports, the U.S. should offer incentives for reshoring—or work to stabilize prices through multilateral frameworks. Without this, tariffs could weaken supply chains, reduce access and ultimately further inflate prices—the very issues the policy aims to fix.
Trump’s Drug Pricing Plan: A Push for Affordability… or Popularity?
Trump’s push to lower U.S. drug prices re-emerged with an executive order signed on May 12. It calls for “most-favored-nation” pricing—benchmarking U.S. drug costs to those in the lowest-cost peer countries—and proposes direct-to-patient sales from manufacturers.
While the order touts price cuts of up to 90%, its potential impact remains limited. Similar efforts under Trump’s first term were blocked in court, and the new order lacks legal weight, a timeline, or defined drug categories. As experts put it, “executive orders are wish lists”.
Still, the strategy marks a shift—leveraging U.S. market power not just to lower domestic prices, but also to pressure foreign governments to raise theirs. EU pharmaceutical executives, seeing increased competitiveness and challenges, have echoed calls for price hikes in Europe to sustain innovation and avoid trade retaliation.
Though the Trump administration has expressed intent to reframe Medicare’s drug price negotiation program, any meaningful pricing relief would still depend on targeting the most used, highest-cost medications covered by federal programs. We therefore reiterate the views expressed in our March 13th note (“Investing in U.S. Healthcare”), which identifies the large pharmaceutical companies and specific drugs most at risk, along with smaller companies worth considering.
The feasibility of achieving large-scale price drops remains difficult due to legal and institutional hurdles—namely, constitutional challenges to price caps and the administrative complexity of implementing negotiated pricing.
That said, the administration has demonstrated its willingness to act elsewhere—most notably through broad-based federal program spending cuts.
Federal Cuts Will Loosen the Safety Net
The “Big, Beautiful Bill” passed by the U.S. House in late May introduces sweeping fiscal changes that, among other things, could drastically reshape the nation’s federal healthcare programs. The legislation proposes nearly $700 billion in Medicaid cuts over a decade, potentially leaving over 10 million people without coverage. Work requirements—80 hours monthly of work, school, or service—would apply broadly for the first time in Medicaid’s 60-year history. Past state-level trials to implement work requirements led to coverage losses without boosting employment, as most recipients are actually already employed or unable to work (as exposed below).
Beyond cutting off millions of people from needed healthcare coverage, the policy threatens companies dependent on these programs. Those most at risks are discussed below.
- Medicaid has become a foundational revenue stream for major U.S. insurers. Nearly 60% of total revenues for the top five insurers now come from Medicare and Medicaid, with public companies like Centene, Molina, UnitedHealth, CVS, and Elevance accounting for half of all Medicaid managed care enrollment. These firms face operational and financial challenges.
- Medicaid is the primary payer for long-term care, covering 61% of total national long-term care spending. This makes the sector particularly exposed to potential funding cuts. For our in-depth analysis on the eldercare segment, refer to our note “The Age of Opportunity: Investments in Eldercare” (April 24, 2025).
For pharmaceutical manufacturers, we identify those whose revenues are significantly tied to Medicaid programs based on the Centers for Medicare & Medicaid Services data. The following table lists publicly traded companies with the highest exposure to Medicaid, by revenue contribution.
Exposure to public reimbursement has long been seen as defensive—but in this case, it’s where the sharpest cuts may land. Note that many of the companies we flagged in the section above as being relatively unaffected by tariffs are nonetheless highly vulnerable to Medicaid cuts, underscoring that pharma companies are suffering from multiple policy cross-currents.
The United States is deeply unsettled by the prospect of losing its global hegemonic status to China, a shift that challenges its national identity. Since the Second World War, America has been positioned as the world’s economic, technological and military leader, a role intertwined with its sense of exceptionalism. China’s rapid ascent, backed by state-led industrial strategy, expanding global influence, and technological ambition, poses a direct threat to U.S. supremacy.
Countries with current account deficits should find it easier to strike deals with the Trump administration because they have more flexibility in reaching a balanced trade position with the USA, i.e. they can buy stuff from the United States to appease politicians. Trump has repeatedly framed global trade as a zero-sum game, where US deficits equate to losses, and surpluses indicate exploitation. This is how Liberation Day was framed where countries with bilateral deficits with the USA had the minimum 10% tariffs and trade surplus countries had much higher tariffs. In this context, countries that run deficits are less threatening and more likely to be dependable trading partners. Moreover, deficit countries often share concerns about global imbalances and may be more amenable to bilateral arrangements that emphasize domestic industry protection, supply chain re-shoring, and nationalist economic policies. The initial information we have on the trade deal between the United Kingdom and the United States is an example where the UK has essentially given a veto to the US to reject Chinese company purchases. The table below highlights some of the countries that run current account deficits. The first deal announced is with the UK. Discussions with India seem to be advancing. The case of Japan is slightly more complicated because its current deficit account status is highly dependent on the price of commodities since they import most of them. With lower commodity prices, a current account deficit will rapidly swing to a surplus. Initial indications are that Japan will be among the early deals. We added Canada to the list, even if it currently runs a surplus, since Canada, Mexico and the USA will probably modify their current trade deal (USMCA). Canada is the opposite of Japan where low commodity prices can swiftly shift it to a current account deficit country.
Countries with large current account surpluses—such as those in the graph below, are likely to face tougher trade negotiations with the United States because they are seen as benefitting disproportionately from global trade. A surplus implies these countries export significantly more than they import, often into large consumer markets like the U.S. The White House argues that imbalances reflect unfair advantages such as undervalued currencies, protectionist policies, or state support for export-driven sectors. The U.S. will demand concessions like greater market access, reduced subsidies, or currency adjustments and tariff rates greater than the minimum 10% are likely to stay for the countries that run current account surpluses. China and re-routing countries such as Indonesia, Vietnam and Malaysia are the main targets. The European Union may also encounter more difficult negotiations than currently expected, even if it is a historical ally.
It is clear that pursuing maximum cost efficiency is no longer the main goal of our evolving economic system; the prospects for globalization are dimming. GDP for consumption sake will get replaced by industrial policy where resiliency is more important and how money is spent counts. For example, investments in the US shipbuilding industry are more important than purchases of dolls even if each dollar spent results in the same when measuring economic output.
Biden used carrots to re-industrialize with the Inflation Reduction Act, the Chips Act and the Infrastructure Bill. Trump is using sticks with tariffs and other coercive measures. Earlier this week, China and the United States announced a 90-day truce period to negotiate a comprehensive trade agreement. During the press conference, Scott Bessent, the US Treasury Secretary, confirmed that the United States is seeking strategic decoupling from China. This helped to reduce the temperature of the trade war, but the direction of travel is clear to both sides. Companies have been warned: do not invest in China, bring your supply chain closer to the consumer and create jobs.
When production is closer to major markets, companies can iterate products faster, ensure better quality control, and maintain greater control over labor and environmental standards. While shorter supply chains may raise production costs, it can reduce exposure to supply risks in a transforming World Order. This change signals a broader move away from a purely globalized efficiency model toward one rooted in strategic autonomy and resilience.
In the context of strategic decoupling, we identified 20 sustainable companies from our investment universe, across sectors and investment themes, that are best positioned to thrive in a deglobalizing world, specifically related to the eventual strategic decoupling of the United States from China.
The table below highlights the 20 companies, their sector, what they do and why they are not affected by the trade conflict.
Next, we examined historical performance over the last 10 years to align with the long perspective of this note. The chart below shows a list of strong performers over the last 10 years in health care (Intuitive Surgical, Vertex and Quest), utilities (Constellation) and energy (Cameco). As we can see, our selection of health care companies have done very well and they remain well-positioned for the upcoming mayhem. Cameco and Constellation Energy are both beneficiaries of the nuclear renaissance.
The following chart shows companies in the same sectors that have some catch up to do. Ormat is a geothermal utility which has not yet benefitted from the same excitement as nuclear but it could come soon since the Trump administration supports geothermal. LKQ is an auto parts recycler and Americold is a cold storage real investment trust which have not been top of mind. Vital Farms is a pasture-raised egg producer that has not yet completely recovered from the pandemic.
The next chart looks at strong performers in technology, industrials and materials. Fortinet and ServiceNow, and even Parker Hannifin benefitted from the strong performance of technology-related companies. Republic Services and Waste Management rode the wave of increased demand and consolidation in waste and recycling.
And finally in the chart below, we look at companies that have lagged in industrials and materials over the last decade. Most of the companies on the chart below were performing very well until recently when the risk of recession increased and engulfed Commercial Metals, First Solar, Freeport, ArcBest and even Packaging Corporation. We believe those companies will benefit from strategic decoupling that will favor local producers and shorter supply chains. Their recent drops in price reflects the risk of a recession emanating from less global commerce. In our view, these companies could reverse higher once/if a recession gets fully reflected in their price.
As we have highlighted in past notes, the world’s population is getting older and this is especially the case in developed countries. Across Europe and North America, the share of persons aged 65 and older will reach 25% by 2040.
These demographic changes create structural demand for senior living facilities. The Baby Boomer generation is living longer, spending more years as a senior, spurring demand for both independent and assisted living as well as residences offering higher levels of care. Furthermore, in the United States, the supply of senior housing is not keeping pace with demand.
In addition to growing demand, senior living facilities’ largely domestic operations make them less vulnerable to tariffs and global supply chain challenges. Obviously, this industry is not without its challenges. Risks include labor shortages whereby stricter immigration policy could affect the high share of foreign-born nursing assistants, and the potential for significant cuts to Medicare depending on how the House-approved budget framework progresses into a formal bill.
Still, amidst the current economic backdrop of stagflation and heightened recession risk, we find this sector attractive. We favor REITs in particular; in addition to less cyclical demand, they are relatively insulated from rising operational costs, which are mainly borne by their tenants, and benefit from stable rental income and inflation pass-through in their lease agreements. Many eldercare REITs also offer attractive dividend yields. Furthermore, within the REITs segment, investors can choose from different business models with distinct risk-return profiles. Given their appeal in the current context, we focus on REITs for the remainder of the note.
The REIT Stuff: A Senior Housing Breakdown
Senior care REITs own and manage assets such as independent living facilities, assisted living facilities and skilled nursing facilities. To screen for these companies, we identified REITs earning at least 65% of revenues from senior housing and with a market capitalization over USD 1 billion. We then excluded companies with a score below 55% in our proprietary ESG-Materiality Score, which assesses factors material to these companies’ impact—namely product responsibility, energy & climate change, and resource management. We also screened for controversies; one might recall the Orpea scandal in France, which highlighted severe governance and human rights failures in senior care. To account for such risks, we excluded companies with either ongoing severe controversies or structural weaknesses in managing ESG risks—such as inadequate responses to past controversies or weak governance and oversight mechanisms. The five resultant companies are presented in the table below.
Within the senior care REIT space, two distinct business models offer different risk-return profiles for investors.
- Triple-Net Lease
Commonly used for skilled nursing facilities, this structure minimizes exposure to operational costs. The REIT leases the facility for a fixed rent and the operator assumes full responsibility for the three main expenses: taxes, maintenance and insurance in addition to the operational costs. This model provides predictable, stable income and insulation from rising operating costs, but limits exposure to revenue growth.
- Senior Housing Operating Portfolio (SHOP)
In contrast, the SHOP model enables the REIT to share in revenue growth by partnering with operators who manage the facilities. In addition to rental income, the REIT is exposed to revenue from resident fees, services and amenities but the landlord also pays more of the property expenses. This offers more upside potential, but also greater volatility.
Though we expect senior care to benefit from strong, non-cyclical demand growth, the ability to choose between these two models – more growth-oriented SHOP or stable-income triple-net – gives investors flexibility in tailoring their exposure based on risk appetite and market outlook.
Three of the companies we identified operate with the triple-net lease model: Omega Healthcare Investors, Cofinimmo and Aedifica. The remaining two, Welltower and Ventas, are mixed between triple-net lease and SHOP, but with greater emphasis on the SHOP model. Given this combined approach we refer to Welltower and Ventas as having a “mixed” strategy for the remainder of the note.
Elder Economics: Performance Drivers for Senior Care REITs
Acquisition strategies play a key role in driving growth for these REITs regardless of their lease structure. Buying properties enables portfolio expansion and diversification across geographic regions and care models. The table below highlights major property acquisitions by Welltower, Ventas and Omega over the past five years.
Welltower, Ventas, and Omega are among the most active acquirers in American healthcare REITs over the past five years. Each has acquired more properties than their peers’ average and for Welltower and Ventas, at higher total transaction values.
For the two European REITs, Cofinimmo and Aedifica, comparable standardized data on acquisitions was not available. However, both appear to have focused less on acquisitions in recent years compared to their American counterparts. Their 2024 annual reports point to a strategic pivot toward upgrading, developing, and maintaining existing senior care facilities, alongside divestments in non-core segments: Aedifica is exiting its portfolio of school buildings in Sweden, while Cofinimmo has accelerated its shift from offices to healthcare, having sold €700 million worth of office assets over the past three years.
Over the past two years, the performance of the highlighted healthcare REITs has diverged significantly, shaped by differences in national markets and strategic activities.
Mixed strategies have outperformed in the past two years. Welltower and Ventas have benefited from rising occupancy and pricing power in senior housing amid strong demand and limited new supply. They acquired assets below replacement cost (purchasing a property for less than what it would cost to build the same asset today) and put strong emphasis on their SHOP segment. Welltower enhanced revenue by converting many triple-net leased properties into SHOP structures, and Venta’s SHOP segment is expected to generate over half of Ventas’s total revenue in 2025.
Among the three triple-net lease companies, Omega Healthcare has significantly outperformed its peers. Aside from higher acquisition activity, a key differentiator versus the European triple-net lease companies is Omega’s exposure to Skilled Nursing Facilities (SNFs), which represent 64% of its portfolio. As the largest U.S. owner of SNFs, Omega benefits from the higher yields typically associated with this asset type. Among the different types of senior care, SNFs have the least elastic demand compared to independent or assisted living facilities but these tenants also have greater operational risks, such as labor and rising costs, due to the higher level of care required. The risk of these tenants is reflected in Omega’s higher cap rate of 6.5% – notably higher than the 3.0% and 4.0% for Welltower and Ventas, respectively. This cap rate serves as a proxy for investment risk. Furthermore, while many seniors depend on Medicare and Medicaid, Omega has 81% of its payor mix from these programs, making it particularly sensitive to any changes.
European peers, Aedifica and Cofinimmo, are subject to greater regulatory constraints, particularly in Belgium and Germany, where rent indexation and pricing flexibility are limited by the structure of public senior care funding. This, coupled with weaker acquisition activity could explain their recent underperformance; however, both companies have delivered strong revenue growth over multiple years and remain well positioned to benefit from long-term demand drivers such as population ageing and the need to modernize care infrastructure. Because of this and their more attractive valuations (see below), we favor them over the riskier Omega in the triple-net lease category. On this basis we eliminate Omega from the rest of our analysis.
Financial Health of Selected REITs
Following our strategic assessment, we now examine the financial fundamentals of the four REITs best positioned for long-term upside.
Here are the main takeaways from this table:
- Growth: Despite greater acquisition activities by their peers, Aedifica has the highest CAGR over a three-year period at 18.9%, followed by Cofinimmo at 10.3%. While the U.S. REITs show stronger short-term momentum, the European triple-net names have delivered steadier long-term growth. Note, Cofinimmo’s dip in revenues in 2024 reflects a strategic repositioning rather than core business weakness, as it scaled back office assets to focus on its healthcare activities.
- Cash-Flow & Profitability: U.S. REITs report Core Funds From Operations (Core FFO), a metric that adjusts net income to better reflect recurring operational performance, used to assess underlying profitability. European peers report EPRA Earnings, a standardized measure that focuses on rental income and excludes fair value changes and one-time items. NOI, or Net Operating Income, captures property-level income before financing and taxes. Welltower posted the strongest growth in both Core FFO and NOI, reflecting strong momentum. In contrast, Ventas showed more modest gains. The triple-net lease REITs reported moderate Core FFO growth and slower NOI expansion—consistent with their model of predictable, inflation-linked lease revenues.
- Valuation: On a Price-to-FFO basis — the REIT equivalent of P/E — Welltower commands a premium multiple, while Ventas, Aedifica, and Cofinimmo are cheaper. The pattern repeats on a NAV basis: Welltower trades at a 79% premium, while Aedifica and Cofinimmo trade at discounts, suggesting potential undervaluation or lower growth expectations for the European names.
- Dividend yields: Higher for the European triple-net REITs, reflecting the stable, inflation-linked nature of their income streams.
- Balance Sheet: Debt metrics are strongest for Welltower, Aedifica, and Cofinimmo, all with debt ratios under 45%. Ventas appears more leveraged by comparison. Interest coverage is particularly solid among the European players. European companies have better occupancy rates (98.5–100%), while mixed-model REITs hover in the mid-80% range — leaving room for upside, but with increased operational risk.
Our top picks of healthcare REITs offer a combination of strong sustainability performance, stable income, and diversified risk-return profiles that can weather both market and policy headwinds. Within the Mixed REITs, Welltower stands out for its recent momentum— though this comes with a premium valuation. Ventas is cheaper but its lower growth and higher leverage temper the appeal. Among the triple-net lease companies, Aedifica and Cofinimmo, stand out for their deep NAV discounts, high and secure dividend yields and strong balance sheets.